Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine augmented with scopolamine for premenstrual dysphoric disorder
IRCT20250219064776N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Mar 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Premenstrual Dysphoric Disorder (PMDD) comparing Fluoxetine + scopolamine with Placebo control (2 arms). Primary endpoint: Change in symptom severity. Started Mar 2025; status: completed.
02
Drugs
fluoxetinescopolamine
03
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Beyond the preview
Go deeper on IRCT20250219064776N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250219064776N1.